Iktos Announces Collaboration With Pfizer in AI for Drug Design
Iktos announced today the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs.
Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in small-molecule drug design. Iktos has been at the forefront of these efforts putting its generative modeling technology at work in several collaborations with pharmaceutical and biotechnology companies. A key aspect of the technology is that exploration of chemical space is performed by generating compounds in silico under the constraints of program endpoints, rather than screening libraries of compounds.
New Strategic report on Virtual Private Cloud VPC Software Market In Depth Insight, Growth & Research Finding TO 2028 – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
Which Service Is a Major Commercial Cloud Platform? {Feb}
dodbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dodbuzz.com Daily Mail and Mail on Sunday newspapers.